Zygogen licenses morpholino antisense technology from the University of Minnesota.

Zygogen, LLC (Atlanta, GA), a biotechnology company that utilizes zebrafish for drug discovery, announced that it has an exclusive license from the University of Minnesota to use morpholino antisense technology in zebrafish. Morpholino antisense, recognized as the best-validated system for effective inhibition of gene function in zebrafish, provides a rapid method for target validation in a living vertebrate model system.

The terms of the agreement include license and royalty payments to the University of Minnesota, which owns the patent for the zebrafish morpholino antisense technology. In addition, Zygogen has the right to sub-license the technology.

"We …